How ILARIS^® Works

ILARIS^® Specifically Addresses Inflammation Caused by IL-1β, a Driving Cause of CAPS (Cryopyrin-Associated Periodic Syndrome)

• IL-1β, also known as interleukin-1 beta, is a protein that is part of the body's immune system
• Overproduction of IL-1β is a driving cause of the inflammation in a rare, genetic condition called CAPS (learn more about CAPS in the section Facts About CAPS
• ILARIS^® (canakinumab) works by specifically addressing the inflammation that results from overproduction of IL-1β

ILARIS^® Works by Blocking IL-1β

• ILARIS^® has been shown to provide relief from the Symptoms of CAPS by blocking IL-1β
• Relief was measured by lab results and by the doctor's evaluation of the patient's skin disease and symptoms as being minimal or better, including symptoms such as:
• Rash
• Fatigue
• Muscle pain
• Headache or migraine
• Sore or red eyes
• Joint pain

ILARIS^® Is Given Only Once Every 8 Weeks

• ILARIS^® provides Complete and Long-Lasting Response when given as an injection only once every 8 weeks—just 6 or 7 treatments in a year
• The ILARIS^® injection may be given by your doctor in office
• Your doctor may also arrange to have the ILARIS^® injection given in your home by a visiting nurse

• 97% of CAPS patients had complete response within the first treatment period (8 weeks). The majority of patients (71%) had complete response in just 7 days
• Complete response was measured by lab results and by the doctor's evaluation of the patient's skin disease and symptoms as being minimal or better, including symptoms such as rash, fatigue, muscle pain, headache or migraine, sore or red eyes, and joint pain
• A flare was measured by lab results and by the doctor's evaluation of the patient's symptoms as being mild or worse, or an evaluation of both the patient's symptoms and skin disease as being minimal or worse

Ask your doctor if ILARIS^® Is Right for You